Literature DB >> 30207220

Oncolytic Virotherapy for Breast Cancer Treatment.

Samia M O Bryan1, J Michael Mathis1.   

Abstract

Breast cancer continues to be a leading cause of mortality among women. While at an early stage, localized breast cancer is easily treated; however, advanced stages of disease continue to carry a high mortality rate. The discrepancy in treatment success highlights that current treatments are insufficient to treat advanced-stage breast cancer. As new and improved treatments have been sought, one therapeutic approach has gained considerable attention. Oncolytic viruses are uniquely capable of targeting cancer cells through intrinsic or engineered means. They come in many forms, mainly from four major virus groups as defined by the Baltimore classification system. These vectors can target and kill cancer cells, and even stimulate immunotherapeutic effects in patients. This review discusses not only individual oncolytic viruses pursued in the context of breast cancer treatment but also the emergence of combination therapies with current or new therapies, which has become a particularly promising strategy for treatment of breast cancer. Overall, oncolytic virotherapy is a promising strategy for increased treatment efficacy for advanced breast cancer and consequently provides a unique platform for personalized treatments in patients. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.

Entities:  

Keywords:  Breast cancer; Clinical trials; Oncolytic; Preclinical; Vectors; Virotherapy; Viruses.

Mesh:

Year:  2018        PMID: 30207220     DOI: 10.2174/1566523218666180910163805

Source DB:  PubMed          Journal:  Curr Gene Ther        ISSN: 1566-5232            Impact factor:   4.391


  10 in total

Review 1.  Clinical Data on Immunotherapy in Breast Cancer.

Authors:  Julia Caroline Radosa; Lisa Stotz; Carolin Müller; Askin Canguel Kaya; Erich-Franz Solomayer; Marc Philipp Radosa
Journal:  Breast Care (Basel)       Date:  2020-10-13       Impact factor: 2.860

2.  CXCL12 Retargeting of an Oncolytic Adenovirus Vector to the Chemokine CXCR4 and CXCR7 Receptors in Breast Cancer.

Authors:  Samia M O'Bryan; J Michael Mathis
Journal:  J Cancer Ther       Date:  2021-06

Review 3.  Pouring petrol on the flames: Using oncolytic virotherapies to enhance tumour immunogenicity.

Authors:  Alicia Teijeira Crespo; Stephanie Burnell; Lorenzo Capitani; Rebecca Bayliss; Elise Moses; Georgina H Mason; James A Davies; Andrew J Godkin; Awen M Gallimore; Alan L Parker
Journal:  Immunology       Date:  2021-03-28       Impact factor: 7.215

4.  A novel cocktail therapy based on quintuplet combination of oncolytic herpes simplex virus-2 vectors armed with interleukin-12, interleukin-15, GM-CSF, PD1v, and IL-7 × CCL19 results in enhanced antitumor efficacy.

Authors:  Han Hu; Siqi Zhang; Linkang Cai; Haixiao Duan; Yuying Li; Junhan Yang; Yang Wang; Biao Liu; Shuang Dong; Zhizheng Fang; Binlei Liu
Journal:  Virol J       Date:  2022-04-22       Impact factor: 5.913

5.  Attenuated measles vaccine strain have potent oncolytic activity against Iraqi patient derived breast cancer cell line.

Authors:  Sulaiman A Abdullah; Ahmed Majeed Al-Shammari; Safaa A Lateef
Journal:  Saudi J Biol Sci       Date:  2019-12-19       Impact factor: 4.219

6.  Combination Therapy of Novel Oncolytic Adenovirus with Anti-PD1 Resulted in Enhanced Anti-Cancer Effect in Syngeneic Immunocompetent Melanoma Mouse Model.

Authors:  Mariangela Garofalo; Laura Bertinato; Monika Staniszewska; Magdalena Wieczorek; Stefano Salmaso; Silke Schrom; Beate Rinner; Katarzyna Wanda Pancer; Lukasz Kuryk
Journal:  Pharmaceutics       Date:  2021-04-14       Impact factor: 6.321

Review 7.  Clinical Trials of Oncolytic Viruses in Breast Cancer.

Authors:  Mary E Carter; André Koch; Ulrich M Lauer; Andreas D Hartkopf
Journal:  Front Oncol       Date:  2021-12-23       Impact factor: 6.244

Review 8.  Oncolytic Virotherapy Treatment of Breast Cancer: Barriers and Recent Advances.

Authors:  Amy Kwan; Natalie Winder; Munitta Muthana
Journal:  Viruses       Date:  2021-06-11       Impact factor: 5.048

9.  Oncolytic Herpes Simplex Virus Encoding IL12 Controls Triple-Negative Breast Cancer Growth and Metastasis.

Authors:  Shanawaz M Ghouse; Hong-My Nguyen; Praveen K Bommareddy; Kirsten Guz-Montgomery; Dipongkor Saha
Journal:  Front Oncol       Date:  2020-03-24       Impact factor: 6.244

Review 10.  Immunotherapy: A Challenge of Breast Cancer Treatment.

Authors:  Marilina García-Aranda; Maximino Redondo
Journal:  Cancers (Basel)       Date:  2019-11-20       Impact factor: 6.639

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.